NCT00842088 - Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2010

Conditions

Sickle Cell Disease

Interventions

DRUG

Placebo

Matching placebo capsule. Administered orally once a day on dosing days.

DRUG

HQK-1001

HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.

Trial Locations (9)

University of the West Indies, Mona, Kingston

Johns Hopkins School of Medicine, Baltimore

UNC Comprehensive Sickle Cell Program, Chapel Hill

Medical College of Georgia, Augusta

Century Clinical Research, Inc., Daytona Beach

Trialogic Research, Madison

University of Illinois at Chicago, Chicago

Texas Children's Cancer Center and Hematology Service, Houston

Children's Hospital and Research Center at Oakland, Oakland